In a substudy of the Partners PreP trial, efficacy was 100% with closely monitored adherence and stepped-up counseling if levels fell below 80%.
Efficacy of pre-exposure prophylaxis (PrEP) in recent trials has ranged from zero to 75%, with the differences explained in large part by disparities in adherence among the studies. In a substudy cohort within the Partners PreP Study (a randomized, placebo-controlled trial of daily oral PrEP among HIV-uninfected members of serodiscordant couples in Kenya and Uganda), investigators optimized study-medication adherence through close surveillance — unannounced home-based pill counts and electronic pill-bottle monitoring — and provided intensive counseling if adherence fell below 80%.
The substudy involved 1147 HIV-seronegative participants (53% men; median age, 34) enrolled from three study sites in Uganda. Ninety-nine percent of them were marr…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)